Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
Cancers · 05.01.2025 · 17 (1) · 146
DOI: 10.3390/cancers17010146 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.01.2025. Verfasst von David Sipos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Faculty of Health Sciences, University of Pécs, 7621 Pécs, Hungary. Die Arbeit wurde bisher 224-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma, the most common and aggressive primary brain tumor in adults, presents a formidable challenge due to its rapid progression, treatment resistance, and poor survival outcomes. Standard care typically involves maximal safe surgical resection, followed by fractionated external beam radiation therapy and concurrent temozolomide chemotherapy. Despite these interventions, median survival remains approximately 12–15 months, with a five-year survival rate below 10%. Prognosis is influenced by factors such as patient age, molecular characteristics, and the extent of resection. Patients with IDH-mutant tumors or methylated MGMT promoters generally have improved survival, while recurrent glioblastoma is associated with a median survival of only six months, as therapies in these cases are often palliative. Innovative treatments, including TTFields, add incremental survival benefits, extending median survival to around 20.9 months for eligible patients. Symptom management—addressing seizures, headaches, and neurological deficits—alongside psychological support for patients and caregivers is essential to enhance quality of life. Emerging targeted therapies and immunotherapies, though still limited in efficacy, show promise as part of an evolving treatment landscape. Continued research and clinical trials remain crucial to developing more effective treatments. This multidisciplinary approach, incorporating diagnostics, personalized therapy, and supportive care, aims to improve outcomes and provides a hopeful foundation for advancing glioblastoma management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Imaging, Faculty of Health Sciences, University of Pécs, 7621 Pécs, Hungary.
- Dr. József Baka Diagnostic, Radiation Oncology, Research and Teaching Center, "Moritz Kaposi" Teaching Hospital, Guba Sándor Street 40, 7400 Kaposvár, Hungary.
- Institute of Pedagogy of Health and Nursing Sciences, Faculty of Health Sciences, University of Pécs, Vörösmarty Str. 4, 7621 Pécs, Hungary.
- Department of Public Health, College of Health Science, Abu Dhabi University, Abu Dhabi P.O. Box 59911, United Arab Emirates.
- Department of Oncoradiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Medical Imaging and Radiotherapy Department, University of Ljubljana, Zdravstvena Pot 5, 100 Ljubljana, Slovenia.
ORCID-Profile: David Sipos, Bence L Raposa, Patrizia Cornacchione, Árpád Kovács
Zitieren
APA
Sipos, D., Raposa, B. L., Freihat, O., Simon, M., Mekis, N., Cornacchione, P., & Kovács, Á. (2025). Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers, 17(1), 146. https://doi.org/10.3390/cancers17010146
Vancouver
Sipos D, Raposa BL, Freihat O, Simon M, Mekis N, Cornacchione P, et al. Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers. 2025;17(1):146. doi:10.3390/cancers17010146
BibTeX
@article{Sipos2025,
author = {Sipos, David and Raposa, Bence L and Freihat, Omar and Simon, Mihály and Mekis, Nejc and Cornacchione, Patrizia and Kovács, Árpád},
title = {Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes},
journal = {Cancers},
year = {2025},
volume = {17},
number = {1},
pages = {146},
doi = {10.3390/cancers17010146}
}
EUVIMED